- Report
- April 2025
- 200 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- April 2025
- 200 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- March 2025
- 200 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- March 2025
- 175 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- February 2025
- 200 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- February 2025
- 200 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- January 2025
- 175 Pages
Global
From €4032EUR$4,490USD£3,439GBP
- Report
- June 2025
- 419 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 377 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 466 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 483 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 377 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 590 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 291 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 285 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 382 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 386 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 211 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 78 Pages
Global
From €5254EUR$5,850USD£4,481GBP
- Report
- June 2025
- 93 Pages
Global
From €5254EUR$5,850USD£4,481GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more